VBI Vaccines Inc (NASDAQ:VBIV)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $0.84, but opened at $0.86. VBI Vaccines shares last traded at $0.83, with a volume of 91,401 shares trading hands.
A number of research analysts recently weighed in on the company. Zacks Investment Research downgraded VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Raymond James started coverage on VBI Vaccines in a research note on Thursday, November 14th. They issued an “outperform” rating and a $3.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. VBI Vaccines has an average rating of “Buy” and a consensus target price of $3.81.
The firm has a market cap of $143.87 million, a price-to-earnings ratio of -0.83 and a beta of 0.79. The firm’s 50-day moving average is $0.64 and its 200-day moving average is $0.87. The company has a current ratio of 1.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01.
In other VBI Vaccines news, CEO Jeff Baxter bought 150,000 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were bought at an average price of $0.50 per share, for a total transaction of $75,000.00. Following the acquisition, the chief executive officer now directly owns 608,255 shares of the company’s stock, valued at approximately $304,127.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven Gillis purchased 10,000,000 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The stock was acquired at an average cost of $0.50 per share, for a total transaction of $5,000,000.00. Over the last three months, insiders have bought 30,212,000 shares of company stock valued at $15,105,440. 10.50% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. purchased a new stake in shares of VBI Vaccines in the second quarter worth approximately $25,000. Citadel Advisors LLC purchased a new position in shares of VBI Vaccines during the second quarter valued at approximately $31,000. Bank of Montreal Can boosted its position in shares of VBI Vaccines by 71.8% during the second quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 15,717 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of VBI Vaccines during the second quarter valued at approximately $58,000. Finally, Weil Company Inc. grew its holdings in VBI Vaccines by 228.6% during the second quarter. Weil Company Inc. now owns 71,875 shares of the biopharmaceutical company’s stock worth $84,000 after buying an additional 50,000 shares in the last quarter. 40.91% of the stock is owned by hedge funds and other institutional investors.
VBI Vaccines Company Profile (NASDAQ:VBIV)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
See Also: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.